https://scholars.lib.ntu.edu.tw/handle/123456789/634957
標題: | First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial | 作者: | Kim, Hye Ryun Sugawara, Shunichi Lee, Jong-Seok Kang, Jin-Hyoung Inui, Naoki Hida, Toyoaki Lee, Ki Hyeong Yoshida, Tatsuya Tanaka, Hiroshi Yang, Cheng-Ta Nishio, Makoto Ohe, Yuichiro Tamura, Tomohide Yamamoto, Nobuyuki CHONG-JEN YU Akamatsu, Hiroaki Takahashi, Shigeru Nakagawa, Kazuhiko |
關鍵字: | bevacizumab; chemotherapy; nivolumab; non-squamous non-small cell lung cancer; survival | 公開日期: | 28-八月-2023 | 來源出版物: | Cancer medicine | 摘要: | ONO-4538-52/TASUKI-52 was performed in Japan, Korea, and Taiwan to determine the oncological effectiveness and safety of combining nivolumab or placebo with bevacizumab plus platinum chemotherapy for the initial (first-line) treatment of patients with advanced non-squamous non-small cell lung cancer (nsNSCLC). At the interim analysis (minimum follow-up, 7.4 months), the independent radiology review committee-assessed progression-free survival was significantly longer in the nivolumab arm, but overall survival (OS) data were immature. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/634957 | ISSN: | 2045-7634 | DOI: | 10.1002/cam4.6348 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。